These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33744274)

  • 41. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
    Bai XY; Zhang XC; Yang SQ; An SJ; Chen ZH; Su J; Xie Z; Gou LY; Wu YL
    PLoS One; 2016; 11(3):e0149370. PubMed ID: 26943330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
    Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
    Huang J; Lan X; Wang T; Lu H; Cao M; Yan S; Cui Y; Jia D; Cai L; Xing Y
    Oncogene; 2020 Feb; 39(8):1739-1755. PubMed ID: 31740781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
    Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
    Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells.
    Ma CS; Lv QM; Zhang KR; Tang YB; Zhang YF; Shen Y; Lei HM; Zhu L
    Acta Pharmacol Sin; 2021 Apr; 42(4):613-623. PubMed ID: 32704041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
    Yu T; Xia Q; Gong T; Wang J; Zhong D
    Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
    Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Limb expression 1-like protein promotes epithelial-mesenchymal transition and epidermal growth factor receptor-tyrosine kinase inhibitor resistance via nucleolin-mediated ribosomal RNA synthesis in non-small cell lung cancer.
    Li M; Zhang J; Meng X; Liu B; Xie SM; Liu F; Yao D; Zhang J; Shen H; Xing L
    Cancer Sci; 2023 Apr; 114(4):1740-1756. PubMed ID: 36478492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Wang Q; Li X; Ren S; Su C; Li C; Li W; Yu J; Cheng N; Zhou C
    Lung Cancer; 2020 Sep; 147():99-105. PubMed ID: 32683208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
    Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
    Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
    Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
    Nilsson MB; Sun H; Robichaux J; Pfeifer M; McDermott U; Travers J; Diao L; Xi Y; Tong P; Shen L; Hofstad M; Kawakami M; Le X; Liu X; Fan Y; Poteete A; Hu L; Negrao MV; Tran H; Dmitrovsky E; Peng D; Gibbons DL; Wang J; Heymach JV
    Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.